Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPXOYJ)

• Drug Name: CPI-0610 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myelofibrosis	2A20.2	Phase 3	[1]
Acute myeloid leukaemia	2A60	Phase 1/2	[2]
Myelodysplastic neoplasm	2A60	Phase 1/2	[2]
Myeloproliferative neoplasm	2A20	Phase 1/2	[2]

• Cross-matching ID:
  PubChem CID: 57389999
  CAS Number: CAS 1380087-89-7
  TTD Drug ID: DMPXOYJ

Molecule-Related Drug Atlas

Drug(s) Targeting Bromodomain-containing protein 4 (BRD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
PLX2853	DMX168L	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
RVX-208	DM1LO8K	Alzheimer disease	8A20	Phase 1/2	[3]
INCB57643	DMBGU7V	Advanced malignancy	2A00-2F9Z	Phase 1/2	[2]
ABBV-744	DMTEA9C	Acute myeloid leukaemia	2A60	Phase 1	[2]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[5]
GSK525762	DMPAWBN	Haematological malignancy	2B33.Y	Phase 1	[3]
TEN010	DM4UOY5	Advanced solid tumour	2A00-2F9Z	Phase 1	[3]
AZD5153	DMW4GM2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PMID26924192-Compound-104	DM346EU	N. A.	N. A.	Patented	[6]

Drug(s) Targeting Bromodomain and extraterminal domain protein (BET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZEN-3694	DM6VQTF	Prostate cancer	2C82.0	Phase 2	[7]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
BMS-986158	DM6LDI4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
INCB054329	DM7TZL0	Refractory hematologic malignancy	2A85.5	Phase 1/2	[8]
INCB057643	DMG65CV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
ODM-207	DMOKVJD	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[11]
GSK525762	DMPAWBN	Haematological malignancy	2B33.Y	Phase 1	[2]
PLX51107	DMXLHVW	Haematological malignancy	2B33.Y	Phase 1	[2]
BI 894999	DM7W5N2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Drug(s) Affected By N-myc proto-oncogene protein (MYCN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[12]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[15]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[17]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[4]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[20]

Drug(s) Affected By Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[21]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[24]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[25]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[26]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[28]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[29]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain and extraterminal domain protein (BET)	TTE4BSY	NOUNIPROTAC	Inhibitor	[2]
Bromodomain-containing protein 4 (BRD4)	TTRA6BO	BRD4_HUMAN	Modulator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)	OT9G360P	IF2B1_HUMAN	Gene/Protein Processing	[4]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Gene/Protein Processing	[4]

References

• [1] ClinicalTrials.gov (NCT04603495) Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
• [4] IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression. Mol Cancer. 2023 May 29;22(1):88. doi: 10.1186/s12943-023-01792-0.
• [5] Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
• [6] BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
• [7] Clinical pipeline report, company report or official report of Zenith Epigenetics.
• [8] The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
• [9] Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
• [10] First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [13] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [14] All-trans-retinoic acid inhibits collapsin response mediator protein-2 transcriptional activity during SH-SY5Y neuroblastoma cell differentiation. FEBS J. 2007 Jan;274(2):498-511. doi: 10.1111/j.1742-4658.2006.05597.x.
• [15] Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. 2007 Jun 4;96(11):1675-83.
• [16] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [17] [Impact of arsenic trioxide on proliferation and metastasis of drug-resistant human ovarian carcinoma cell line]. Ai Zheng. 2002 Aug;21(8):863-7.
• [18] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [19] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [20] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [21] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [22] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [23] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [24] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [25] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [26] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [27] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [28] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [29] METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis. Cell Biol Toxicol. 2023 Jun;39(3):1015-1035. doi: 10.1007/s10565-021-09660-7. Epub 2021 Oct 14.
• [30] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.